BioMarin Pharmaceutical Inc. is a biotechnology company focused on developing medicines for individuals with genetically defined conditions. The company has a portfolio of nine commercial therapies and a pipeline of clinical and preclinical candidates, primarily targeting rare diseases. BioMarin employs a drug discovery approach rooted in genetic insights, aiming to address the underlying genetic changes associated with these conditions. It operates globally, with a presence in approximately 80 countries.
